Related Experiment Video
Updated: Aug 14, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.2K
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer:
Amar U Kishan1,2, Ting Martin Ma1, James M Lamb1
1Department of Radiation Oncology, University of California, Los Angeles.
JAMA Oncology
|January 12, 2023
Summary
MRI-guided stereotactic body radiotherapy (SBRT) significantly reduced genitourinary and gastrointestinal toxic effects in prostate cancer patients compared to CT-guidance. This approach also improved patient-reported quality of life outcomes.
Area of Science:
- Oncology
- Radiotherapy
- Medical Imaging
Background:
- Magnetic resonance imaging (MRI) guidance theoretically enhances stereotactic body radiotherapy (SBRT) for prostate cancer.
- Previous studies lacked randomized clinical trial (RCT) data to confirm these advantages.
Purpose of the Study:
- To evaluate if MRI-guided SBRT with reduced margins decreases acute genitourinary (GU) toxicity compared to CT-guided SBRT.
- To assess the impact on gastrointestinal (GI) toxic effects and patient-reported outcomes.
Main Methods:
- Phase 3 RCT (MIRAGE trial) involving men with prostate adenocarcinoma.
- Randomized 1:1 to SBRT with CT guidance (4 mm margins) or MRI guidance (2 mm margins).
- Primary endpoint: acute grade 2+ GU toxic effects; Secondary endpoints: GI toxic effects, IPSS, EPIC-26 scores.
Main Results:
- MRI-guided SBRT showed significantly lower rates of acute grade 2+ GU toxic effects (24.4% vs 43.4%, P=.01).
- Significantly reduced acute grade 2+ GI toxic effects were observed with MRI guidance (0.0% vs 10.5%, P=.003).
- MRI guidance led to fewer patients reporting increased IPSS and decreased EPIC-26 bowel scores at 1 month.
Conclusions:
- MRI-guided SBRT significantly reduces acute physician-scored toxic effects compared to CT-guided SBRT.
- MRI guidance also mitigates decrements in patient-reported quality of life.
- Further follow-up is needed to confirm the persistence of these benefits.
